VIP (vasoactive intestinal peptide): selected references HeartPep literature library, reviewed 2026-11-09 https://heartpep.com/us/research/library/vip 1. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP (2001). Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease Nature Medicine. DOI: https://doi.org/10.1038/87887 PMID: 11329057 Source: https://pubmed.ncbi.nlm.nih.gov/11329057/ Verification: Abstract / bibliographic record. 2. Brown SM, Barkauskas CE, Grund B, et al. (2023). Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial The Lancet Respiratory Medicine. DOI: https://doi.org/10.1016/S2213-2600(23)00147-9 PMID: 37348524 Source: https://pubmed.ncbi.nlm.nih.gov/37348524/ Verification: Full text. These are selected background references, not evidence that a HeartPep product or batch matches a studied preparation. Cite and assess the original papers.